EMA Authorised: Prevenar 20 (previously Apexxnar) (Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 3;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6A;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 8;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 10A;Pneumococcal polysaccharide serotype 11A;pneumococcal polysaccharide serotype 12F;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 15b;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19A;Pneumococcal polysaccharide serotype 19F;Pneumococcal polysaccharide serotype 22F;Pneumococcal polysaccharide serotype 23F;Pneumococcal polysaccharide serotype 33F) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Prevenar 20 (formerly Apexxnar), a 20-valent pneumococcal conjugate vaccine by Pfizer, for vaccination against pneumococcal infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevenar 20 (pneumococcal conjugate vaccine 20-valent)

Snippet

Status: Authorised. Therapeutic area: Pneumococcal Infections. MAH: Pfizer Europe MA EEIG. Decision date: 23/10/2025